Moderna's mRNA Flu Vaccine, mFLUSIVA, Gains FDA Approval for Adults 50+
Moderna has received Food and Drug Administration approval for its mRNA-based flu vaccine, mFLUSIVA, for individuals aged 50 and older, despite a contentious review process.
Archive
Moderna has received Food and Drug Administration approval for its mRNA-based flu vaccine, mFLUSIVA, for individuals aged 50 and older, despite a contentious review process.
